Cantor Fitzgerald Estimates ALX Oncology FY2024 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Equities researchers at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for ALX Oncology in a research report issued to clients and investors on Tuesday, November 12th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($2.69) per share for the year, up from their prior forecast of ($3.08). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.86) per share.

Other equities research analysts also recently issued reports about the stock. Stifel Nicolaus restated a “hold” rating and issued a $3.00 target price (down from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. UBS Group dropped their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a report on Friday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a report on Tuesday, August 13th. Finally, Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.50.

ALX Oncology Stock Down 3.0 %

Shares of NASDAQ:ALXO opened at $1.29 on Friday. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $68.04 million, a price-to-earnings ratio of -0.43 and a beta of 1.03. The stock’s 50-day moving average price is $1.69 and its two-hundred day moving average price is $5.49. ALX Oncology has a 12-month low of $1.25 and a 12-month high of $17.83.

Institutional Trading of ALX Oncology

A number of institutional investors have recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co acquired a new position in shares of ALX Oncology during the first quarter worth about $27,000. EntryPoint Capital LLC acquired a new stake in ALX Oncology in the first quarter valued at approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the period. Rhumbline Advisers raised its stake in shares of ALX Oncology by 10.8% during the second quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock valued at $333,000 after purchasing an additional 5,360 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares in the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.